Compare CNOB & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNOB | ANIP |
|---|---|---|
| Founded | 1982 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 1995 | 1999 |
| Metric | CNOB | ANIP |
|---|---|---|
| Price | $32.19 | $74.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $31.25 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 379.7K | 342.7K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | 1.51 | ★ 2.32 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | $42.85 | $21.01 |
| Revenue Next Year | $7.27 | $17.59 |
| P/E Ratio | ★ $21.37 | $32.48 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $23.20 | $70.15 |
| 52 Week High | $34.14 | $99.50 |
| Indicator | CNOB | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 44.09 | 39.03 |
| Support Level | $31.36 | N/A |
| Resistance Level | $33.95 | $83.43 |
| Average True Range (ATR) | 0.52 | 2.55 |
| MACD | -0.13 | -0.13 |
| Stochastic Oscillator | 23.18 | 9.26 |
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets, and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental, and consumer wages.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.